Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available.
Napolitano, M., Saccullo, G., Marietta, M., Carpenedo, M., Castaman, G., Cerchiara, E., et al. (2019). Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. BLOOD TRANSFUSION, 17(3), 171-180 [10.2450/2018.0143-18].
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus
Napolitano, Mariasanta
;Siragusa, Sergio
2019-01-01
Abstract
Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Lavoro BT.pdf
Solo gestori archvio
Tipologia:
Post-print
Dimensione
1.74 MB
Formato
Adobe PDF
|
1.74 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
171-180_0143-18.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
1.53 MB
Formato
Adobe PDF
|
1.53 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
